AbCellera Biologics has entered into a preclinical research collaboration, option, and license agreement with Jazz Pharmaceuticals to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The partnership will focus on creating treatments for multiple gastrointestinal (GI) cancers and other solid tumors, leveraging AbCellera's antibody discovery platform.
Key Details
- Financial Terms: AbCellera will receive $56 million in upfront payments for two initial programs, plus an additional $28 million upon initiation of a third program. The company is also eligible for up to $792 million per program in potential milestone payments and tiered royalties on net sales.
- Agreement Scope: The collaboration covers two initial research programs, with a commitment to start a third within 12 months. Jazz Pharmaceuticals holds an exclusive option to develop and commercialize any resulting therapeutic antibodies.
- Therapeutic Focus: The partnership aims to deliver optimized development candidates for T-cell engaging (TCE) therapies targeting difficult-to-treat solid tumors, particularly GI cancers.